Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers VANCOUVER, British Columbia, Sept. 16, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or the “Company“), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a Health Canada-authorized Phase 3 clinical trial evaluating MDMA (3,4-methylenedioxymethamphetamine)-assisted therapy for individuals with post-traumatic stress disorder (“PTSD“). The trial is expected to begin in 2027. The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline...

Milestone follows FDA clearance of MAIA’s amended investigational new drug (IND) submission highlighting improved manufacturing capabilities and efficiencies  U.S. expansion is funded by a $2.3 million NIH grant to MAIA to support third-line treatment evaluation CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the first U.S. patient has been dosed in its Phase 2 THIO-101 trial expansion evaluating its telomere-targeting lead candidate, ateganosine, in third-line non-small cell lung cancer (NSCLC). The U.S. Phase 2 expansion is funded by a $2.3 million grant from the National Institutes of Health (NIH) to support third-line treatment evaluation...

New data presented in Vienna highlights long-term repeat-dose modeling, mechanistic GI barrier profiling, and deconvolution of payload- and linker-dependent toxicities for complex modalities SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — VivoSim Labs, Inc. (NASDAQ: VIVS) (“VivoSim” or the “Company”) unveils new clinical benchmark data at the 58th Congress of the European Societies of Toxicology (EUROTOX 2026) in Vienna, Austria, demonstrating the ability of its NAMkind™ 3D human liver and intestinal platforms to predict drug toxicity across small molecules and increasingly complex therapies, including Antibody-Drug Conjugates (ADCs). The new data strengthens VivoSim’s positioning in the growing market for human-relevant predictive toxicology and New Approach Methodologies (NAMs), as pharmaceutical companies increasingly...

New digital technologies, including Synchrony and SynX, will be featured at HRX Stereotaxis CEO to join main-stage panel on Autonomous EP SystemsST. LOUIS, Sept. 16, 2026 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that its portfolio of digital and robotic technologies will be featured at Heart Rhythm Society’s HRX conference, taking place September 18-20, 2026, in Atlanta, Georgia. Pioneered by the Heart Rhythm Society, HRX brings together clinicians, engineers, and entrepreneurs to explore advances in connectivity, artificial intelligence and automation in cardiovascular medicine. Synchrony, Stereotaxis’ integrated lab display, and SynX, its cloud-based connectivity platform will be among the technologies featured...

FORM 8.5 (EPT/RI) Amendment in 1(b) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)        Name of exempt principal trader: Investec Bank Plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree Tribal Group Plc(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Joint Broker to Tribal Group Plc(d)        Date dealing undertaken: 14th September 2026(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash...

CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). “Activation of UF Health as a QTC represents an important step in expanding access to ZEVASKYN for patients living with RDEB in Florida and the Southeastern United States,” said Dr. Madhav Vasanthavada, Chief Commercial Officer of...

380 Meter Hole Completed at Vumba Central; Core Logging Identifies Silica–Carbonate Alteration, Quartz–Carbonate Veining and Sulfides; Full Hole Sampling Planned Second Drill Hole Underway as Company Advances Approximately 3,000-Meter 2026 Program TORONTO, Sept. 16, 2026 (GLOBE NEWSWIRE) — One Bullion Ltd. (“One Bullion” or the “Company”) (TSXV: OBUL), a gold exploration company holding complete ownership of three highly prospective exploration projects in Botswana, today announced the completion of diamond drill hole VUDD017 to a final depth of 380 meters at its wholly owned Vumba Gold Project in northeastern Botswana. VUDD017 marks the completion of the first hole of the Company’s approximately 3,000-meter 2026 diamond drilling program, with drilling now underway on the next hole, VUDD018. The hole tested the Central–Makoba target...